Complement-mediated tumor-specific cell lysis by antibody combinations targeting epidermal growth factor receptor (EGFR) and its variant III (EGFRvIII)

Cancer Science

Volumn 102, Issue 10, 2011, Pages 1761-1768

  Klausz, Katja ^a   Berger, Sven ^a   Lammerts van Bueren, Jeroen J ^b   Derer, Stefanie ^a   Lohse, Stefan ^a   Dechant, Michael ^a   van de Winkel, Jan G J ^b   Peipp, Matthias ^a   Parren, Paul W H I ^b   Valerius, Thomas ^a  

^a UNIVERSITY OF KIEL   (Germany)

^b GENMAB   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; MONOCLONAL ANTIBODY 13.1.2; MONOCLONAL ANTIBODY CH806; MONOCLONAL ANTIBODY MR1 1; MONOCLONAL ANTIBODY MRI IE3; UNCLASSIFIED DRUG; ZALUTUMUMAB;

ANTIBODY AFFINITY; ANTIBODY BLOOD LEVEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY DETECTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER IMMUNOTHERAPY; CELL ISOLATION; CELL STRAIN HEK293; COMPLEMENT ACTIVATION; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; CYTOLYSIS; DRUG TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MONOCYTE; MONONUCLEAR CELL; POLYMORPHONUCLEAR CELL; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; CELL LINE, TUMOR; CHO CELLS; COMPLEMENT SYSTEM PROTEINS; CRICETINAE; CYTOTOXICITY, IMMUNOLOGIC; EPITOPE MAPPING; HEK293 CELLS; HUMANS; NEUTROPHILS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 80053386362     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2011.02019.x     Document Type: Article

References (43)

1. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003; 21: 2787-99.
2. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 2008; 358: 1160-74.
3. Kumar A, Petri ET, Halmos B, Boggon TJ. Structure and clinical relevance of the epidermal growth factor receptor in human cancer. J Clin Oncol 2008; 26: 1742-51.
4. Machiels JP, Subramanian S, Ruzsa A et al. Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomized phase 3 trial. Lancet Oncol 2011; 12: 333-43.
5. Peipp M, Dechant M, Valerius T. Effector mechanisms of therapeutic antibodies against ErbB receptors. Curr Opin Immunol 2008; 20: 436-43.
6. Bibeau F, Lopez-Crapez E, Di Fiore F et al. Impact of FcγRIIa-FcγRIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol 2009; 27: 1122-9.
7. Zhang W, Gordon M, Schultheis AM et al. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol 2007; 25: 3712-8.
8. Dechant M, Weisner W, Berger S et al. Complement-dependent tumor cell lysis triggered by combinations of epidermal growth factor receptor antibodies. Cancer Res 2008; 68: 4998-5003.
9. Pedersen MW, Jacobsen HJ, Koefoed K et al. Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy. Cancer Res 2010; 70: 588-97.
10. Peipp M, Dechant M, Valerius T. Sensitivity and resistance to EGF-R inhibitors: approaches to enhance the efficacy of EGF-R antibodies. MAbs 2009; 1: 590-9.
11. Lorimer IA. Mutant epidermal growth factor receptors as targets for cancer therapy. Curr Cancer Drug Targets 2002; 2: 91-102.
12. Pedersen MW, Meltorn M, Damstrup L, Poulsen HS. The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy. Ann Oncol 2001; 12: 745-60.
13. Sampson JH, Heimberger AB, Archer GE et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol 2010; 28: 4722-9.
14. Johns TG, Mellman I, Cartwright GA et al. The antitumor monoclonal antibody 806 recognizes a high-mannose form of the EGF receptor that reaches the cell surface when cells over-express the receptor. FASEB J 2005; 19: 780-2.
15. Johns TG, Adams TE, Cochran JR et al. Identification of the epitope for the epidermal growth factor receptor-specific monoclonal antibody 806 reveals that it preferentially recognizes an untethered form of the receptor. J Biol Chem 2004; 279: 30375-84.
16. Keyt BA, Liu Y, Chen F et al. Human antibody drug conjugates specific to the mutant EGF receptor (EGFRvIII) inhibit tumor growth observed with in vitro and in vivo models of glioma. Proc Amer Assoc Cancer Res 2004; 45: #700 (Abstract).
17. Dechant M, Vidarsson G, Stockmeyer B et al. Chimeric IgA antibodies against HLA class II effectively trigger lymphoma cell killing. Blood 2002; 100: 4574-80.
18. Beyer T, Lohse S, Berger S, Peipp M, Valerius T, Dechant M. Serum-free production and purification of chimeric IgA antibodies. J Immunol Methods 2009; 346: 26-37.
19. Bendig M, Saldanha J, Kettleborough CA. Humanized and chimeric monoclonal antibodies that bind epidermal growth factor receptor (EGF-R). Patent EP1362868, 2003.
20. Old LJ, Johns TG, Panousis C et al. Specific binding proteins and uses thereof. Patent US20090220510, 2009.
21. Pastan I, Beers R, Chowdhury PS, Bigner D. Anti-egfrvIII scfvs with improved cytotoxicity and yield, immunotoxins based thereon, and methods of use thereof. Patent US20030211097, 2003.
22. Weber R, Feng X, Foord O et al. Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof. Patent US20090155282, 2009.
23. Idusogie EE, Wong PY, Presta LG et al. Engineered antibodies with increased activity to recruit complement. J Immunol 2001; 166: 2571-5.
24. Bleeker WK, Lammerts van Bueren JJ, van Ojik HH et al. Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy. J Immunol 2004; 173: 4699-707.
25. Jutten B, Dubois L, Li Y et al. Binding of cetuximab to the EGFRvIII deletion mutant and its biological consequences in malignant glioma cells. Radiother Oncol 2009; 92: 393-8.
26. Lammerts van Bueren JJ, Bleeker WK, Brannstrom A et al. The antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra- and intermolecular flexibility. Proc Natl Acad Sci USA 2008; 105: 6109-14.
27. Kuan CT, Wikstrand CJ, Archer G et al. Increased binding affinity enhances targeting of glioma xenografts by EGFRvIII-specific scFv. Int J Cancer 2000; 88: 962-9.
28. Hadjipanayis CG, Machaidze R, Kaluzova M et al. EGFRvIII antibody-conjugated iron oxide nanoparticles for magnetic resonance imaging-guided convection-enhanced delivery and targeted therapy of glioblastoma. Cancer Res 2010; 70: 6303-12.
29. Ohno M, Natsume A, Ichiro Iwami K et al. Retrovirally engineered T-cell-based immunotherapy targeting type III variant epidermal growth factor receptor, a glioma-associated antigen. Cancer Sci 2010; 101: 2518-24.
30. Jiang H, Wang H, Tan Z et al. Growth suppression of human hepatocellular carcinoma xenografts by a monoclonal antibody CH12 directed to epidermal growth factor receptor variant III. J Biol Chem 2011; 286: 5913-20.
31. Luwor RB, Johns TG, Murone C et al. Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR. Cancer Res 2001; 61: 5355-61.
32. Sampson JH, Crotty LE, Lee S et al. Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors. Proc Natl Acad Sci USA 2000; 97: 7503-8.
33. Weinstein IB. Cancer. Addiction to oncogenes - the Achilles heal of cancer. Science 2002; 297: 63-4.
34. Lutterbuese R, Raum T, Kischel R et al. T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells. Proc Natl Acad Sci USA 2010; 107: 12605-10.
35. Peipp M, Schneider-Merck T, Dechant M et al. Tumor cell killing mechanisms of epidermal growth factor receptor (EGFR) antibodies are not affected by lung cancer-associated EGFR kinase mutations. J Immunol 2008; 180: 4338-45.
36. Schlaeth M, Berger S, Derer S et al. Fc-engineered EGF-R antibodies mediate improved antibody-dependent cellular cytotoxicity (ADCC) against KRAS-mutated tumor cells. Cancer Sci 2010; 101: 1080-8.
37. Schneider-Merck T, Lammerts van Bueren JJ, Berger S et al. Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid lineage. J Immunol 2010; 184: 512-20.
38. Tiroch K, Stockmeyer B, Frank C, Valerius T. Intracellular domains of target antigens influence their capacity to trigger antibody-dependent cell-mediated cytotoxicity. J Immunol 2002; 168: 3275-82.
39. Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a key system for immune surveillance and homeostasis. Nat Immunol 2010; 11: 785-97.
40. Moore GL, Chen H, Karki S, Lazar GA. Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions. MAbs 2010; 2: 181-9.
41. Taylor RP, Lindorfer MA. Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies. Curr Opin Immunol 2008; 20: 444-9.
42. Hsu YF, Ajona D, Corrales L et al. Complement activation mediates cetuximab inhibition of non-small cell lung cancer tumor growth in vivo. Mol Cancer 2010; 9: 139.
43. Perera RM, Narita Y, Furnari FB et al. Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity. Clin Cancer Res 2005; 11: 6390-9.